» Articles » PMID: 38996940

2-(Piperidin-3-yl)phthalimides Reduce Classical Markers of Cellular Inflammation in LPS-challenged RAW 264.7 Cells and Also Demonstrate Potentially Relevant Sigma and Serotonin Receptor Affinity in Membrane Preparations

Overview
Specialty Biochemistry
Date 2024 Jul 12
PMID 38996940
Authors
Affiliations
Soon will be listed here.
Abstract

Herein, we report the synthesis of new 4-amino-2-(piperidin-3-yl)isoindoline-1,3-diones and their biological evaluation in a series of in vitro experiments. The synthetic production of these materials was initiated upon the condensation of appropriate nitrophthalic acid derivatives with various 3-aminopiperidines; subsequent reduction provided the final products in moderate to good yields. Readily available chiral pool reagents facilitated entry into optically enriched samples, while the piperidine scaffold furnished a variety of amide and alkylated entries. In total, 16 candidates were produced, and their ensuing treatment in LPS-challenged RAW cells effected slight reductions in secreted TNF-α but provided more robust and dose-dependent declines in nitrite and IL-6 levels relative to basal amounts, all concurrent with maintenance of cellular viability across the concentration ranges screened. The secondary amine cohort including rac-6, (R)-7, and (S)-8 rendered the most pronounced dose-dependent reductions in nitrite and IL-6. When dosed at 30 μM, (R)-7 demonstrated the most compelling effects, with decreases of 32 % and 40 % for nitrite and IL-6, respectively. Notable reductions in the inflammatory markers were also observed for 19 which effected declines in TNF-α (14 %), nitrite (19 %), and IL-6 (11 %) when treated at 30 μM. Additionally, four representative compounds were further evaluated against numerous CNS receptors, channels, and transporters, with 6, 9, and 19 demonstrating varying degrees of nanomolar-to-low-micromolar binding to the σ-1 and σ-2 receptors and also to serotonin receptors 5HT, 5HT and 5HT. In this regard, 6 displayed perhaps the most noteworthy affinities, with binding at σ-2 (K = 2.2uM), 5HT (K = 561 nM) and 5HT (K = 536 nM). Furthermore, no pronounced or dose-dependent Cereblon/DDB1 binding was observed for the screened representative compounds 6, 9, 18 and 19.

References
1.
Chen L, Ni X, Zhang H, Wu M, Liu J, Xu S . Preparation, characterization, in vitro and in vivo anti-tumor effect of thalidomide nanoparticles on lung cancer. Int J Nanomedicine. 2018; 13:2463-2476. PMC: 5922239. DOI: 10.2147/IJN.S159327. View

2.
Monassier L, Laplante M, Jaffre F, Bousquet P, Maroteaux L, de Champlain J . Serotonin 5-HT(2B) receptor blockade prevents reactive oxygen species-induced cardiac hypertrophy in mice. Hypertension. 2008; 52(2):301-7. DOI: 10.1161/HYPERTENSIONAHA.107.105551. View

3.
Kale R, Tayade P, Saraf M, Juvekar A . Molecular encapsulation of thalidomide with sulfobutyl ether-7 beta-cyclodextrin for immediate release property: enhanced in vivo antitumor and antiangiogenesis efficacy in mice. Drug Dev Ind Pharm. 2008; 34(2):149-56. DOI: 10.1080/03639040701484486. View

4.
Robinson G, Li D, Wang B, Zahoruiko Y, Gerasymchuk M, Hudson D . Anti-Inflammatory Effects of Serotonin Receptor and Transient Receptor Potential Channel Ligands in Human Small Intestinal Epithelial Cells. Curr Issues Mol Biol. 2023; 45(8):6743-6774. PMC: 10453699. DOI: 10.3390/cimb45080427. View

5.
Besnard J, Ruda G, Setola V, Abecassis K, Rodriguiz R, Huang X . Automated design of ligands to polypharmacological profiles. Nature. 2012; 492(7428):215-20. PMC: 3653568. DOI: 10.1038/nature11691. View